臨床婦人科産科61巻10号

2007年10月発行

今月の臨床 ここまできた分子標的治療 分子標的治療の臨床応用

3．HPVを分子標的としたワクチン開発

著者： 井上正樹¹

所属機関： ¹金沢大学医学系研究科産婦人科学

ページ範囲：P.1262 - P.1269

はじめに

　子宮癌は古くから性行為との関連が疑われ媒体となる種々のものが想定され検証されてきたが，実証には至らなかった．20世紀後半の分子生物学の技術的進歩を背景として1983年，zur Hausenらによって子宮頸部癌組織にHPV（human papillomavirus）16型ゲノムが高率に存在することが報告され，原因ウイルスとして急速に注目された^1）．そして，多くの研究者がHPV研究に参画し，疫学研究や分子レベルの基礎研究が進められHPVが子宮頸癌の原因ウイルスであることが明確になった^2）．今日，これらHPV研究の成果は臨床現場で生かされようとしている．がん検診への導入やワクチンの開発である．子宮頸部癌の撲滅が現実のものとなりつつある．医学の進歩による素晴らしい成果といえよう．

参考文献

1）Durst M, Gissmann L, Ikenperg H : A papillomavirus DNA from a cervical carcinoma and its prevalence in cervical biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80 : 3812─3815, 1983

2）Zur Hauzen H : Human papillomaviruses in the pathogenesis of anogenital cancer. Virol 184 : 9─13, 1991

3）Kiyonot T, Hiraiwa A, Fujita M, et al : Binding of high─risk human papillomaviorus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci 94 : 11612─11616, 1997

4）Segawa，Sasagawa T, Yamazaki H, et al : The inverse relationship between FHIT abnormalities and HPV E6─E7 m RNA expression in the development of cervical Cancer. Cancer 85 : 2001─2010, 1999

5）Zur Hausen H : Papillomavirus and cancer. From basic studies to clinical application. Nature Review 5 : 342─350, 2002

6）Sasagawa T, Inoue M, Tanizawa O, et al : Identification of antibodies against human papillomavirus type 16E6 and E7 proteins in sera of the patients with cervical neoplasias. Jpn J Cancer Res 83 : 705─713, 1992

7）Roden R, Wu TC : How will HPV vaccine affect cervical cancer? Nature Review Cancer 6 : 753─763, 2006

8）Borysiewicz LK, Fiander A, Nimako M, et al : A recombinant vaccinia virus encoding human papillomavirus type16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347 : 1523─1527, 1996

9）Brulet JM, Maudoux F, Thomas S, et al : DNA vaccine encoding endosome─targeted human papillomavirus type 16E7 protein generates XD4＋T cell─dependent protection. Eur J Immunol 37 : 310─314, 2007

10）Ji H, Wang TL, Chen CH, et al : Targeting HPV─16 E7 to the endosomal／lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV─16 E7─expresing tumor. Human Gene Therapy 10 : 2727─2740, 1999

11）Klencke B, Matijevic M, Urban RG, et al : Encapsulated plasmid DNA treatment for human papillomavirus 16─associated anal dysplasia : a Phase I study of ZYC101. Clin Caner Res 8 : 1028─1037, 2002

12）Sheets EE, Urban RG, Crum CP, et al : Immunotherapy of human cervical high─grade cervical intraepithelial neoplasia with microparticle─derived human papillomavirus 16E6 plasmid DNA. Am J Obstet Gynecol 188 : 916─926, 2003

13）Garcia F, Petry KU, Muderspach L, et al : ZYC101a for treatment of high─grade cervical intra-epithelial neoplasia : a randomized controlled trial. Obstet Gynecol 103 : 317─326, 2004

14）Zhou J, Sun XY, Stenzel DJ, et al : Expression of vaccine recombinant HPV 16L1 and L2 proteins in epithelial cells is sufficient for assembly of HPV virion─like particles. Virology 185 : 251─257, 1991

15）Kirnbauer R, Booy F, Cheng N, et al : Papillomavirus L1 major capsid protein self─assembles into virus─like particles that are highly immunogenic. Proc Natl Acad Sci USA 89 : 12180─12184, 1992

16）Sasagawa T, Inoue M, Lehtinen M, et al : Serological response to human papillomavirus type 6 and 16 virus like particles in patients with cervical neoplastic lesions. Clin Diagn Lab Immunol 3 : 403─410, 1996

17）Sasagawa T, Yamazaki H, Dong YZ, et al : Immu─noglobulin─A and ─G responses against virus─like particles（VLP）of human papillomavirus type 16 in women with cervical cancer and cervical intar─epithelial lesions. Int J Cancer 75 : 529─535, 1998

18）Koutsky LA, Ault KA, Wheeler CM, et al : A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 : 1645─1651, 2002

19）Kondo K, Ishii Y, Ochi H, et al : Neutralization of HPV16,18,31,and 58 pseudovirions with antisera synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virol 358 : 266─272, 2007

20）Inoue M, Nakazawa A, Fujita M, et al : Human papillomavirus type 16 in semen of partners of women with HPV infection. Lancet 339 : 1114─1115, 1992

21）Stanley M : Prophylactic HPV vaccines. J Clin Pathol 60 : 961─965, 2007

22）Harper DM, Franco FL, Wheeler CM, et al : Sustained efficacy up to 4.5 years of a bivalent L1 virus─like particle vaccine against human papillmavirus types 16 and 18 : follow─up from a rando mized control trial. Lancet 367 : 1247─1255, 2006

23）Bosch FX, Manos MM, Maños N, et al : International biological study on cervical cancer study group ; a prevalence of human papillomavirus in cervical cancer : world wide perspective. J Natl Cancer Inst 87 : 796─802, 1995

24）Wu TH, Hutt JA, Garrison KA, et al : Intranasal vaccination induces protective immunity against intranasal virulent Francisella Tularensis Biovar A. Infect Immun 73 : 2644─2654, 2005

25）Colgrove J : The ethics and politics of compulsory HPV vaccination. N Engl J Med 355 : 2389─2391, 2006